by a growing
Bone Neoplasia Program
This program is chaired by Marc Hansen, Ph.D. The group is comprised of faculty from multiple disciplines and interacts with the Musculoskeletal Signature Program. The Bone Program is organized to understand primary bone tumorigenesis and secondary metastasis to bone in the context of normal bone development and remodeling. Bone is both a storage source of cytokines critical to tumorigenesis and an important developmental process. It is also the only developmental process that is regulated by gravitational stress and loading.
As a storage source of cytokines, bone is an important site of metastasis for breast and prostate as well as other types of cancer. Both breast and prostate cancer subvert normal bone signaling pathways to facilitate their metastatic phenotype. Primary bone tumorigenesis appears to arise as a result of the deregulation of the normal bone developmental process. A better understanding of the normal regulatory processes that take place during bone remodeling, a time during which rapid proliferation of osteoblasts and osteoclasts occurs, and the role of the extracellular matrix laid down during bone development will improve our understanding of these same processes that are unregulated during both primary tumorigenesis as well as secondary metastasis.
Cancer Immunology Program
This program is led by Pramod Srivastava, Ph.D., M.D., and includes doctorally-prepared scientists and physician-scientists engaged in basic and translational research.
Investigators in the Center for Immunotherapy of Cancer and Infectious Disease study basic mechanisms of immune response, and their application to treatment of cancers. The research addresses NK cell function, T cell priming, induction of tolerance, innate immunity, antigen processing and presentation.
This program serves as the paradigm for translational research. There are vaccine trials in CML, ovarian cancer, renal cell, melanoma and cervical pre-invasive neoplasia.
Genetics/Developmental Biology Program
This program is led by Marc LaLande, Ph.D. There are several doctorally-prepared scientist engaged in basic research and clinical service throughout the Genomics and Molecular Cores. The Gene Targeting and Transgenic Facility is focused on the development of mouse models of human disease.
Departmental faculty also supervises an institutional Genomics Core comprised of a cDNA microarray core facility and a Molecular Core. The Microarray Core facility provides access to a state-of-the-art technology for gene expression profiling, a powerful tool for simultaneous monitoring of the expression levels for very large sets of genes. The Molecular Core offers full service automated DNA sequencing.
Molecular Medicine Program
This program is led by Andrew Arnold, M.D. There are several doctorally-prepared faculty engaged in human disease-oriented laboratory research in the Center for Molecular Medicine.
Dr. Arnold's laboratory investigates the molecular genetic basis of tumors of the endocrine glands. The cyclin D1 oncogene, initially discovered by Dr. Arnold in parathyroid tumors, has a broad role in human cancer and its action in breast cancer is specifically being investigated. Dr. Arnold's laboratory is also pursuing their recent discovery of the major genetic basis of parathyroid gland cancers.
Dr. Jennifer Tirnauer is uniquely merging her scientific expertise in microtubule and cytoskeletal biology with her commitment to cancer research, and is investigating the role of microtubule defects in the abnormal cellular architecture found in breast and colon cancer, among others.
Dr. Marc Hansen investigates the molecular basis of tumors of bone, including study of a new tumor suppressor gene discovered in his laboratory. Center for Molecular Medicine investigator
Dr. Anne Delany participates in the Bone Program as well, and is investigating the molecular mechanisms by which tumors, particularly prostate cancer, metastasize to bone.
Dr. Daniel Rosenberg is active in colon cancer research, as further described in the Molecular GI Cancer Program.
Oral Oncology Program
The Oral Oncology research program is centered in the School of Dental Medicine and Neag Comprehensive Cancer Center. Laboratory and clinical studies are being conducted relative to causes and treatment of oral cancer as well as management of effects of high-dose cancer therapies on the mouth. The collaboration includes clinical and research faculty and staff in the School of Dental Medicine, School of Medicine and Graduate School at UConn Health, as well as researchers from the Graduate School at UConn, Storrs.
This multiprofessional approach continues to identify novel ways to successfully manage cancer patients. Patients treated in the Neag Comprehensive Cancer Center may qualify for participation in state-of-the-science oral oncology clinical trials in this context. The research model is directly linked to the University of Connecticut research mission that in turn is designed to improve the health of Connecticut citizens.
Vascular Biology Program
|The Center for Vascular Biology conducts state-of-the-art research in the area of tumor angiogenesis, lipid mediators, signal transduction, vascular proteomics, post-transcriptional gene expression, vascular developmental biology and cell invasion/metastasis.
Phase 1 Study of OncoImmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Principal Investigator: Angela Kueck, M.D.
The U.S. Food and Drug Administration (FDA) has approved our Investigational Drug Application for this clinical study at UConn Health for patients with advanced stage (stage III or IV) ovarian cancer. Patients shall receive the standard of care treatment including surgery and chemotherapy, followed by a personalized cancer vaccine, which will be developed for each patient. Blood and cancer samples will be obtained from each patients at the time of surgery, and shall be used to generate and compare the genomic information in each patient’s cancer. Personalized vaccines will be made on basis of the genetic differences between the blood and cancer samples of each patient. The patients shall receive the vaccines by an injection in an outpatient setting, once every month for 6 months.
An application will be submitted to the UConn Institutional Review Board (IRB) to initiate the study. Once the IRB approves the study, we will start accruing patients, most likely during September 2015.
In the News